10106974NANOZYME - Endo-metritis therapy for dairy cows – combining tissue release and infection controlActiveCollaborative R&DInnovate UKEndometritis is among the most important and challenging diseases in the dairy industry, with significant animal welfare, economic, and food security consequences. The current standard of care is to administer antibiotics; however, there is growing concern about acquired antimicrobial resistance ("the slow-moving pandemic") and broad agreement that alternatives are needed. In addition, residual tissue such as foetal membranes and placenta often left within the reproductive canal are major predisposing factors, contributing to infections, inflammation, and impaired fertility. Through the collaboration of the established German Pharmaceutical SME (Veyx-Pharma GmbH) with a rapidly growing and clinical-stage UK SME (Tecrea Ltd) and with combined Innovate UK and BMWK support, the proposed project will develop a farmer-centered local treatment for endometritis that avoids the use of antibiotics. This will be achieved using components of Veyx's Masti Veyxym (r) know-how with Tecrea's Nanocin(tm) polymeric nanoparticle ("polyplex") technology to improve placental release and infection control in the birth canal. If successful, the solution will be exploited in a global cattle healthcare market forecast to reach $75.49 by 2029 offering a significantly improved non-antibiotic infection control therapy helping reduce production losses and support optimised reproductive capabilities across the dairy industry.